{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:06:50Z","timestamp":1770347210783,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alpha-1 antitrypsin deficiency (AATD) is a condition caused by the inheritance of two mutated SERPINA1 gene alleles. Individuals with AATD are at increased risk of injury to the liver and lungs. The pulmonary manifestations include precocious onset of pulmonary emphysema and bronchiectasis. For nearly three decades, treatment has been available to individuals with emphysema caused by AATD, but this therapy\u2014augmentation of plasma and tissue alpha-1 antitrypsin levels by intravenous administration of human plasma-derived protein\u2014was approved by regulatory authorities based on its biochemical efficacy. This therapy appears to slow the progression of emphysema in patients with AATD. The medical, patient, and regulatory communities have sought assurance that this expensive therapy provides measurable clinical benefit. Documenting such benefit has been difficult because of the slow progression of the underlying lung disease in AATD, the rarity of this genetic condition, and the lack of direct quantitative measurements of emphysema progression. Over the past decade, quantitative computed tomography (CT) densitometry of the lungs has been found to correlate with severity and progression of emphysema. The recent publication of a well-powered, masked, placebo-controlled study using CT densitometry to evaluate the effectiveness of augmentation therapy at slowing the progression of emphysema has provided some assurance of the clinical efficacy of this therapy.<\/jats:p>","DOI":"10.1513\/annalsats.201510-684kv","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T13:23:11Z","timestamp":1472217791000},"page":"S370-S373","source":"Crossref","is-referenced-by-count":6,"title":["Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-2485","authenticated-orcid":false,"given":"Robert A.","family":"Sandhaus","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care Medicine, and Sleep, National Jewish Health, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"2026020402540169300_bib1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI110360","article-title":"Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects","volume":"68","author":"Gadek","year":"1981","journal-title":"J Clin Invest"},{"key":"2026020402540169300_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","article-title":"Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema","volume":"316","author":"Wewers","year":"1987","journal-title":"N Engl J Med"},{"key":"2026020402540169300_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/ajrccm.158.1.9712017","article-title":"Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin: the Alpha-1-Antitrypsin Deficiency Registry Study Group","volume":"158","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020402540169300_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000196336","article-title":"Serial measurements of FEV1 over 12 years in a patient with alpha-1-protease inhibitor deficiency: influence of augmentation therapy and infections","volume":"61","author":"Wencker","year":"1994","journal-title":"Respiration"},{"key":"2026020402540169300_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1183\/09031936.98.11020428","article-title":"Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin: Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group","volume":"11","author":"Wencker","year":"1998","journal-title":"Eur Respir J"},{"key":"2026020402540169300_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1378\/chest.119.3.737","article-title":"Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor","volume":"119","author":"Wencker","year":"2001","journal-title":"Chest"},{"key":"2026020402540169300_bib7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1183\/09031936.97.10102260","article-title":"Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group","volume":"10","author":"Seersholm","year":"1997","journal-title":"Eur Respir J"},{"key":"2026020402540169300_bib8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","article-title":"A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy","volume":"160","author":"Dirksen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020402540169300_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.00159408","article-title":"Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency","volume":"33","author":"Dirksen","year":"2009","journal-title":"Eur Respir J"},{"key":"2026020402540169300_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1465-9921-11-136","article-title":"Therapeutic efficacy of \u03b1-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry","volume":"11","author":"Stockley","year":"2010","journal-title":"Respir Res"},{"key":"2026020402540169300_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"2026020402540169300_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007851.pub2","article-title":"Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease","volume":"7","author":"G\u00f8tzsche","year":"2010","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/Supplement_4\/S370\/66667365\/annalsats_13_supplement_4_s370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/Supplement_4\/S370\/66667365\/annalsats_13_supplement_4_s370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:54:13Z","timestamp":1770191653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/13\/Supplement_4\/S370\/8449169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":12,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2016,8,1]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201510-684kv","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,8,1]]}}}